Literature DB >> 24998898

A chemical screen identifies small molecules that regulate hepcidin expression.

Vera Gaun1, Bonnie Patchen1, Josephine Volovetz1, Aileen W Zhen1, Aleksandr Andreev1, Michael P Pollastri2, Paula G Fraenkel3.   

Abstract

Hepcidin, a peptide hormone produced in the liver, decreases intestinal iron absorption and macrophage iron release via effects on ferroportin. Bone morphogenic protein and Stat3 signaling regulate Hepcidin's transcription. Hepcidin is a potential drug target for patients with iron overload syndromes because its levels are inappropriately low in these individuals. To generate a tool for identifying small molecules that modulate Hepcidin expression, we stably transfected human hepatocytes (HepG2) cells with a reporter construct containing 2.7kb of the human Hepcidin promoter upstream of a firefly reporter gene. We used high throughput methods to screen 10,169 chemicals in duplicate for their effect on Hepcidin expression and cell viability. Regulators were identified as chemicals that caused a change >3 standard deviations above or >1 standard deviation below the mean of the other chemicals (z-score >3 or <1), while not adversely affecting cell viability, quantified by fluorescence assay. Following validation assays, we identified 16 chemicals in a broad range of functional classes that promote Hepcidin expression. All of the chemicals identified increased expression of bone morphogenic protein-dependent and/or Stat3-dependent genes, however none of them strongly increased phosphorylation of Smad1,5,8 or Stat3.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Bone morphogenic protein; Hemochromatosis; Interleukin-6; Stat3; Thalassemia

Mesh:

Substances:

Year:  2014        PMID: 24998898      PMCID: PMC4198503          DOI: 10.1016/j.bcmd.2014.06.002

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  63 in total

1.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  c-Myc inhibition negatively impacts lymphoma growth.

Authors:  Ilsa Gomez-Curet; R Serene Perkins; Ryan Bennett; Katherine L Feidler; Stephen P Dunn; Leslie J Krueger
Journal:  J Pediatr Surg       Date:  2006-01       Impact factor: 2.545

3.  Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.

Authors:  Emilio Ramos; Piotr Ruchala; Julia B Goodnough; Léon Kautz; Gloria C Preza; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

4.  Hepcidin in iron overload disorders.

Authors:  George Papanikolaou; Michalis Tzilianos; John I Christakis; Dionisios Bogdanos; Konstantina Tsimirika; Julie MacFarlane; Y Paul Goldberg; Nikos Sakellaropoulos; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

5.  In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.

Authors:  X Xu; J Shen; J W Mall; J A Myers; W Huang; L Blinder; T J Saclarides; J W Williams; A S Chong
Journal:  Biochem Pharmacol       Date:  1999-11-01       Impact factor: 5.858

6.  Presumptive hepatotoxicity and rhabdomyolysis secondary to phenazopyridine toxicity in a dog.

Authors:  Melissa L Holahan; Meryl P Littman; Cristine L Hayes
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2010-06

7.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

8.  A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates.

Authors:  Keegan S Cooke; Beth Hinkle; Hossein Salimi-Moosavi; Ian Foltz; Chadwick King; Palaniswami Rathanaswami; Aaron Winters; Shirley Steavenson; C Glenn Begley; Graham Molineux; Barbra J Sasu
Journal:  Blood       Date:  2013-08-14       Impact factor: 22.113

Review 9.  Manipulation of the hepcidin pathway for therapeutic purposes.

Authors:  Eileen Fung; Elizabeta Nemeth
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

10.  Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

Authors:  Corey Cutler; Pratik Multani; David Robbins; Haesook T Kim; Thuy Le; Jonathan Hoggatt; Louis M Pelus; Caroline Desponts; Yi-Bin Chen; Betsy Rezner; Philippe Armand; John Koreth; Brett Glotzbecker; Vincent T Ho; Edwin Alyea; Marlisa Isom; Grace Kao; Myriam Armant; Leslie Silberstein; Peirong Hu; Robert J Soiffer; David T Scadden; Jerome Ritz; Wolfram Goessling; Trista E North; John Mendlein; Karen Ballen; Leonard I Zon; Joseph H Antin; Daniel D Shoemaker
Journal:  Blood       Date:  2013-08-30       Impact factor: 22.113

View more
  10 in total

Review 1.  Anemia of Inflammation: A Review.

Authors:  Paula G Fraenkel
Journal:  Med Clin North Am       Date:  2016-12-24       Impact factor: 5.456

2.  Dietary supplementation with ipriflavone decreases hepatic iron stores in wild type mice.

Authors:  Bonnie Patchen; Tiago Koppe; Aaron Cheng; Young Ah Seo; Marianne Wessling-Resnick; Paula G Fraenkel
Journal:  Blood Cells Mol Dis       Date:  2016-05-08       Impact factor: 3.039

Review 3.  Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Authors:  Jing Liu; Bingbing Sun; Huijun Yin; Sijin Liu
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  Imatinib and spironolactone suppress hepcidin expression.

Authors:  Katarzyna Mleczko-Sanecka; Ana Rita da Silva; Debora Call; Joana Neves; Nikolai Schmeer; Georg Damm; Daniel Seehofer; Martina U Muckenthaler
Journal:  Haematologica       Date:  2017-04-06       Impact factor: 9.941

Review 5.  Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis.

Authors:  Zachary J Hawula; Daniel F Wallace; V Nathan Subramaniam; Gautam Rishi
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-25

6.  A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity.

Authors:  Hongxuan Feng; Xin Hu; Xin Sun; Wang Zheng; Houda G Khaled; Pan P Li; Dobrila D Rudnicki; Wenjuan Ye; Yu-Chi Chen; Noel Southall; Juan Marugan; Christopher A Ross; Marc Ferrer; Mark J Henderson; Russell L Margolis
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

Review 7.  [Progress on epigenetic regulation of iron homeostasis].

Authors:  Lingyan Duan; Xiangju Yin; Hong'en Meng; Xuexian Fang; Junxia Min; Fudi Wang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

Review 8.  Ferroptosis and Its Multifaceted Roles in Cerebral Stroke.

Authors:  Yongfa Zhang; Xiaoyang Lu; Bai Tai; Weijia Li; Tao Li
Journal:  Front Cell Neurosci       Date:  2021-06-03       Impact factor: 5.505

Review 9.  Pharmacological Targeting of the Hepcidin/Ferroportin Axis.

Authors:  Giada Sebastiani; Nicole Wilkinson; Kostas Pantopoulos
Journal:  Front Pharmacol       Date:  2016-06-21       Impact factor: 5.810

10.  Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.

Authors:  Sant-Rayn Pasricha; Pei Jin Lim; Tiago L Duarte; Carla Casu; Dorenda Oosterhuis; Katarzyna Mleczko-Sanecka; Maria Suciu; Ana Rita Da Silva; Kinda Al-Hourani; João Arezes; Kirsty McHugh; Sarah Gooding; Joe N Frost; Katherine Wray; Ana Santos; Graça Porto; Emmanouela Repapi; Nicki Gray; Simon J Draper; Neil Ashley; Elizabeth Soilleux; Peter Olinga; Martina U Muckenthaler; Jim R Hughes; Stefano Rivella; Thomas A Milne; Andrew E Armitage; Hal Drakesmith
Journal:  Nat Commun       Date:  2017-09-01       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.